(0.32%) 5 116.22 points
(0.31%) 38 357 points
(0.38%) 15 988 points
(-0.98%) $83.03
(5.36%) $2.03
(0.35%) $2 355.30
(0.50%) $27.67
(4.20%) $960.85
(-0.27%) $0.932
(-0.44%) $10.98
(-0.58%) $0.796
(1.63%) $93.37
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 10.22%
@ $3.36
発行日: 15 2月 2024 @ 03:54
リターン: 25.19%
前回のシグナル: 2月 14 - 23:30
前回のシグナル:
リターン: 4.19 %
Live Chart Being Loaded With Signals
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis...
Stats | |
---|---|
本日の出来高 | 197 664 |
平均出来高 | 582 479 |
時価総額 | 249.54M |
EPS | $0 ( 2024-03-14 ) |
次の収益日 | ( $-0.0800 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -6.56 |
ATR14 | $0.00800 (0.19%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-12 | Machatha Stephen | Sell | 11 537 | Common Stock |
2024-03-11 | Greenberg Bruce | Sell | 13 201 | Common Stock |
2024-04-05 | Perceptive Advisors Llc | Buy | 37 712 | Common Stock |
2024-04-04 | Perceptive Advisors Llc | Buy | 140 281 | Common Stock |
2024-04-03 | Perceptive Advisors Llc | Buy | 309 847 | Common Stock |
INSIDER POWER |
---|
17.42 |
Last 100 transactions |
Buy: 8 132 048 | Sell: 3 580 213 |
ボリューム 相関
Aldeyra Therapeutics Inc 相関
10 最も負の相関 | |
---|---|
ORTX | -0.975 |
DLHC | -0.959 |
ISTR | -0.957 |
RETA | -0.953 |
THRN | -0.953 |
ESSA | -0.949 |
FRBK | -0.948 |
FMIV | -0.946 |
INO | -0.945 |
DAWN | -0.944 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Aldeyra Therapeutics Inc 相関 - 通貨/商品
Aldeyra Therapeutics Inc 財務諸表
Annual | 2023 |
収益: | $0 |
総利益: | $-262 780 (0.00 %) |
EPS: | $-0.640 |
FY | 2023 |
収益: | $0 |
総利益: | $-262 780 (0.00 %) |
EPS: | $-0.640 |
FY | 2022 |
収益: | $0 |
総利益: | $-258 707 (0.00 %) |
EPS: | $-1.050 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-1.070 |
Financial Reports:
No articles found.
Aldeyra Therapeutics Inc
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。